Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: J Am Coll Clin Pharm. 2019 Jun 29;2(4):373–382. doi: 10.1002/jac5.1160

Table 3.

Comparison of MTM Delivery to Beneficiaries Receiving CMRs by Community Pharmacists and Other Pharmacist Provider Types in 2014

104,303 (100%)
CMR Provided By:
Community RPh
n (%)
Plan RPh
n (%)
p-value MTM Vendor In-House RPh
n (%)
p-value
Total Beneficiaries by Provider Status 26,337 (25.3%) 35,741 (34.3%) 42,225 (40.5%)
Entry into MTM Program
Days from Plan Enrollment to MTM Enrollment
  Mean 68.4 (78) 72.9 (83) 79.5 (78)
  Median 31 48 <0.001c 33 <0.001d
  25th Percentile 0 0 26
  75th Percentile 100 111 119
Days from MTM Enrollment to CMR Offer, n (%)
  Mean (SD) 30.5 (33) 17.8 (29) 20.4 (20)
  Median 28 9 <0.001§ 16 <0.001
  25th Percentile 9 0 4
  75th Percentile 38 26 28
  0 174 (0.7%) 11,071 (31.0%) 1,004 (2.4%)
  1–30 16,757 (63.6%) 18,394 (51.5%) 32,157 (76.2%)
  31–60 7915 (30.1%) 5004 (14.0%) 7757 (18.4%)
  61+ 1491 (5.7%) 1263 (3.5%) 1178 (2.8%)
  Unknown 0 (0.0%) 9 (0.0%) 129 (0.3%)
Days from CMR Offer to First CMR Received
  Mean 85.5 (86) 101.4 (85) 116.6 (93)
  Median 47 76 <0.001§ 94 <0.001
  25th Percentile 20 32 31
  75th Percentile 140 155 194
Part D Contract Type, n (%) 0.394 <0.001
  Managed Care 19,643 (74.6%) 26,543 (74.3%) 19,734 (46.7%)
  Prescription Drug Plan 6690 (25.4%) 9188 (25.7%) 22,323 (52.9%)
  Employer Sponsored 4 (0.0%) 10 (0.0%) 168 (0.4%)
   MTM Services Received
CMR Delivery Method, n (%) <0.001 <0.001
  Face-to-Face 13,010 (49.4%) 380 (1.1%) 9 (0.0%)
  Telephone 13,327 (50.6%) 35,361 (98.9%) 42,216 (100.0%)
  Telehealth Consultation (Video Conferencing) 0 (0.0%) 0 (0.0%) 0 (0.0%)
CMR Recipient <0.001 <0.001
  Beneficiary 23,281 (88.4%) 32,261 (90.3%) 36,246 (85.8%)
  Beneficiary’s Prescriber 53 (0.2%) 7 (0.0%) 14 (0.0%)
  Caregiver/Other Authorized Individual 3003 (11.4%) 3473 (9.7%) 5965 (14.1%)
Mean Number of CMRs Received (SD) 1.01 (0.1) 1.02 (0.1) <0.001 1.03 (0.2) <0.001
Mean Number of Targeted Medication Reviews (SD) 10.29 (8.9) 5.71 (6.7) <0.001 18.36 (18) <0.001
MTM Interventions Made
  Mean Number of MTP Recommendations Made to Prescribers (SD) 1.80 (3.5) 1.17 (2.5) <0.001 1.64 (2.8) <0.001
  Mean Number of MTP Resolutions With Prescribers (SD) 0.22 (0.7) 0.33 (0.9) <0.001 0.35 (0.8) <0.001

CMR = comprehensive medication review; MTM = Medication Therapy Management; MTP = medication therapy problem; RPh = pharmacist; SD = standard deviation.

P-values represent comparisons using t-tests (continuous variables) or chi-square tests (categorical variables) between community pharmacist and plan pharmacist cohorts.

P-values represent comparisons using t-tests (continuous variables) or chi-square tests (categorical variables) between community pharmacist and MTM Vendor In-house pharmacist cohorts.

§

P-values represent comparisons using Wilcoxon rank sum tests between community pharmacist and plan pharmacist cohorts.

P-values represent comparisons using Wilcoxon rank sum tests between community pharmacist and MTM Vendor In-house pharmacist cohorts.